Abbott Laboratories ABT
103.00 USD -0.87 (-0.84%)
Regular-session close
103.00 0.00 0.00%
After hours · Nov 20, 7:46 PM ET
102.80 Day range 105.50
82.56 52-week range 128.90
- YTD
- -17.79%
- 1 year
- -16.92%
News
247wallst.com Abbott Has Raised Its Dividend for 54 Years. These 3 Healthcare Stocks Keep Paying More One dividend streak spans five decades, another company barely paid anything until 2021, and a third pays out a fraction of its earnings. Three healthcare payers raised income this year, but their…
zacks.com Abbott (ABT) Up 1.3% Since Last Earnings Report: Can It Continue? Abbott (ABT) reported earnings 30 days ago. What's next for the stock?
fool.com 3 Dividend Kings to Buy in November and Never Sell Abbott boasts 54 straight years of dividend growth, and plans to spin off its troubled nutrition division could lead to a re-rating of the stock. McDonald's has raised its dividend for 50 years, and…benzinga.com Abbott Initiates VOYAGER CE Clinical Trial Evaluating Investigational Encantor Transcatheter Aortic Valve Implantation Software-Guided Balloon-Expandable System For Treating Symptomatic Severe Aortic Stenosis Abbott's Encantor system includes software-guided deployment technology designed to help optimize valve expansion to the patient's unique anatomy, supporting precise implantation and consistent valve
prnewswire.com Abbott initiates VOYAGER clinical trial for investigational Encantor™ software-guided balloon-expandable TAVI system to treat aortic stenosis Abbott's Encantor system includes software-guided deployment technology designed to help optimize valve expansion to the patient's unique anatomy, supporting precise implantation and consistent valve…
benzinga.com This Abbott Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This Abbott Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Wall Street analysts upgraded RGA, BRO, ABT, FMX and MRSH, raising price targets and outlooks across reinsurance, insurance, healthcare and beverages.benzinga.com Leerink Partners Upgrades Abbott Laboratories to Outperform, Announces $124 Price Target Leerink Partners analyst Mike Kratky upgrades Abbott Laboratories (NYSE:ABT) from Market Perform to Outperform and announces $124 price target.
benzinga.com Ken Griffin Dumps SpaceX, Amazon; Buys ARKK and Bets Big on Marvell Inside Citadel's Q3 13F: Ken Griffin slashed AMD and Amazon, raised Marvell 729%, and quietly unwound Leopold Aschenbrenner's AI fund.
seekingalpha.com The Winners Inside SCHD - November 2026 The SCHD dividend ETF has extended its year-to-date lead over SPY to more than 20%, despite recent market volatility. October was SCHD's best month of 2026, with a nearly 10% gain; 43 holdings have…
zacks.com Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026 ABT's EP business gains momentum as Volt adoption accelerates and new device launches expand its portfolio despite LAA market weakness.
gurufocus.com Is ABT Overvalued? DCF Says Worth $76 On November 16, 2026, we delve into the DCF analysis for Abbott Laboratories (ABT), a company that has seen a challenging year with its stock price reflecting a
defenseworld.net 11,649 Abbott Laboratories $ABT Shares Bought by AlTi Global Inc. AlTi Global Inc. increased its position in shares of Abbott Laboratories (NYSE: ABT) by 114.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange…
benzinga.com Abbott Touts Favorable Outcomes In Cardiovascular Device Trials Abbott reports positive trial results for its Amulet 360 LAA occluder and SonicForce coronary IVL system at a conference.benzinga.com Abbott Announces One-Year Results For Its Amulet 360 Left Atrial Appendage Occluder From The VERITAS Study; Data Show Meaningful Closure Rates Of Left Atrial Appendage And A Low Incidence Of Stroke In People With Atrial Fibrillation Not Caused By A Heart Valve Issue The data were presented in a late-breaking session at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego, Calif., on Nov. 1, 2026, and simultaneously published in JACC:…
benzinga.com Reported Sunday, Abbott’s TECTONIC Trial Of Investigational SonicForce Coronary IVL System Meets Primary Safety And Effectiveness Endpoints, With 0.3% 30-Day Target Lesion Failure And 97% Procedural Success In 335 Patient SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in coronary…
benzinga.com Abbott Initiates CROWN-MV Pivotal Trial Evaluating Safety And Effectiveness Of Its Investigational Cephea Mitral Valve System For Symptomatic Mitral Valve Disease CROWN-MV pivotal trial evaluating the safety and effectiveness of its investigational Cephea™ Mitral Valve System in treating people with symptomatic mitral valve disease who are not candidates for…
benzinga.com This M&T Bank Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded M&T Bank, Bank of Hawaii, HubSpot, Abbott and Moderna; Bank of Hawaii cut its target, while HubSpot’s rose.benzinga.com Abbott Announces Commercial Availability Of Oncodetect Molecular Residual Disease Test Abbott (NYSE: ABT) today announced the commercial availability of its next-generation Oncodetect® MRD test, a personalized, tumor-informed, whole-genome sequencing test designed to provide molecular…
benzinga.com Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $120 Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $119 to $120.
benzinga.com Abbott's New Beta-CORRECT Data At ESMO Congress Demonstrates 30% Enhancement In Sensitivity For Colorectal Cancer Recurrence Within Two Years Of Surgery Abbott (NYSE:ABT) today announced new Beta-CORRECT data presented at the European Society for Medical Oncology (ESMO) Congress showing that the whole-genome sequencing (WGS)-based Oncodetect®…
benzinga.com Citigroup Maintains Buy on Abbott Laboratories, Lowers Price Target to $122 Citigroup analyst Joanne Wuensch maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $125 to $122.
benzinga.com RBC Capital Maintains Outperform on Abbott Laboratories, Lowers Price Target to $125 RBC Capital analyst Kendall Au maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $130 to $125.
benzinga.com Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $119 Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $112 to $119.
benzinga.com JP Morgan Maintains Overweight on Abbott Laboratories, Lowers Price Target to $118 JP Morgan analyst Robbie Marcus maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $120 to $118.
benzinga.com TD Cowen Maintains Buy on Abbott Laboratories, Lowers Price Target to $118 TD Cowen analyst Joshua Jennings maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $135 to $118.
benzinga.com Baird Maintains Outperform on Abbott Laboratories, Raises Price Target to $123 Baird analyst David Rescott maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target from $121 to $123.
benzinga.com BTIG Maintains Buy on Abbott Laboratories, Lowers Price Target to $125 BTIG analyst Marie Thibault maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $134 to $125.
finance.yahoo.com Skydance Corporation (SKYD) Skydance completed its Warner Bros. Discovery merger and is now focused on integrating assets, cutting costs, and reducing substantial debt. Recent coverage highlights a director’s approximately $1…
finance.yahoo.com Abbott Has Raised Its Dividend for 54 Years. These 3 Healthcare Stocks Keep Paying More One dividend streak spans five decades, another company barely paid anything until 2021, and a third pays out a fraction of ...
seekingalpha.com Our Top 10 High Growth Dividend Stocks - November 2026 The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and ...
autoevolution.com This Audi RS3 Sportback Is a 630-Horsepower Mega Hatch Besides the impressive power boost, this ABT-tuned Audi RS 3 Sportback also boasts a few extras inside and out, and is capped ...
seekingalpha.com 10 Best CEFs This Month: Average Yield Of 11% (November 2026) The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an ...
finchannel.com J&J’s $300 Target Puts Growth and Valuation in Focus JPMorgan lifts Johnson & Johnson’s target while keeping Neutral. Earnings, cash flow and legal obligations frame a 12-month ...
ad-hoc-news.de Abbott Laboratories stock: Leerink upgrades rating and target Abbott Laboratories stock drew a higher rating from Leerink Partners on November 19. The firm lifted its price target to 124 ...
247wallst.com Abbott Has Lost More Than 10% This Year, and $1,000 From Five Years Ago Is Worth Less Than $950 Abbott bought a $21 billion cancer screening business and still watched investors flee. A buyer from a decade ago is thrilled ...
